recombinant trypsinogen/chymotrypsinogen (Rec-PRP) / Propanc Biopharma - LARVOL DELTA

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities (Businesswire) - "Propanc Biopharma, Inc...today announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors. Funds will also be utilized to advance the Company’s back up clinical candidate, Rec-PRP, a synthetic recombinant version of PRP, which will further enhance the potency and stability of the naturally derived proenzyme treatment. As part of the process, the opportunity to consider up-listing to a national US stock exchange will also be considered. The emerging boutique advisory firm currently has a $3B+ transaction history and access to a global network of investors the Company intends to fully utilize."

Financing • Oncology • Solid Tumor

"Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program https://t.co/wJK3kl2s5c" (@NewsFromBW)

"Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program https://t.co/ixW8qa9vY2" (@NewsFromBW)